NEW YORK CITY, NY / ACCESS Newswire / December 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ:UNCY). Investors who purchased Unicycive securities prior to March 29, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/UNCY.
Investigation Details
The investigation concerns whether Unicycive and certain of its officers and/or directors have engaged in corporate wrongdoing.
What's Next?
If you are aware of any facts relating to this investigation or purchased Unicycive shares, you can assist this investigation by visiting the firm's site: bgandg.com/UNCY. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Nathan Miller332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS NewswireCOMTEX_470745805/2457/2025-12-02T11:11:49
2.81% $0.18
